Advertisement

Archives of Dermatological Research

, Volume 297, Issue 5, pp 185–189 | Cite as

Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies

  • D. PirardEmail author
  • P. Vereecken
  • C. Mélot
  • M. Heenen
Hot Clinical Study

Abstract

Three percent diclofenac in 2.5% hyaluronan gel (DHA) is approved by the Food and Drug Administration (FDA) in the treatment of actinic keratoses (AK). We conducted a meta-analysis of the few prospective studies that evaluated the effect of DHA on the target lesion number score TLNS0 (indicating complete resolution of all target lesions in the treatment area) and/or the cumulative target lesion number score CLNS0 (indicating resolution of the target and new lesions in the treatment area) with assessment 30 days after the end of treatment. A comprehensive search of the 1966–2005 MEDLINE database and review of the reference lists of relevant articles identified the published randomised trials. Three studies were included, with a total of 364 patients. The placebo was the hyaluronan vehicule gel (HAV). The intention-to-treat analyses show that DHA significantly improve the TLNS0 (OR= 3.72; 95% CI=2.05–6.74) and the CLNS0 (OR=4.09; 95% CI=2.55–6.56) compare to HAV. Overall, 42/106 (39.6% CI: 30.8– 49.1%) had a TLNS0 with mean treatment duration of 75 days ± 21 [mean±standard deviation (SD)], and 70/179 (39.1% CI:32.3–46.4%) patients had a CLNS0 with a mean 78 days±16 treatment duration. DHA is effective compared to HAV in the treatment of AK. Further studies should establish subgroup analyses according to sites and severity of the AK lesions in order to determine if more patients could be improved in restricted indications. Biopsies, a longer follow-up evaluation, and comparisons with the other treatments of AK will also be helpful in the future to define the place of this treatment in the management of AK.

Keywords

Diclofenac Hyaluronan Actinic keratosis Meta-analysis 

References

  1. 1.
    Adamson DJA, Frew D, Tatoud R et al (2002) Diclofebac antagonizes peroxisome proliferator-activated receptor-γ signalling. Mol Pharmacol 61:7–12CrossRefPubMedGoogle Scholar
  2. 2.
    Alam CAS, Seed MP, Willoughby DA (1995) Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol 47:407–411PubMedGoogle Scholar
  3. 3.
    Arrich J, Piribauer F, Mad P et al (2005) Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 172:1039–1043PubMedGoogle Scholar
  4. 4.
    Brown MB, Mariott C, Martin GP (1995) A study of the transdermal drug delivery properties of hyaluronan. Round Table Series 40:53–71Google Scholar
  5. 5.
    Brown M, Jones S (2005) Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 19:308–318CrossRefPubMedGoogle Scholar
  6. 6.
    Buckman SY, Gresham A, Hale P et al (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19:723–729CrossRefPubMedGoogle Scholar
  7. 7.
    Burkhart CN, Burkhart CG (2002) Reassessment of topical diclofenac/hyaluronan gel for actinic keratoses. Int J Dermatol 41:371–373CrossRefPubMedGoogle Scholar
  8. 8.
    Cabrera PV, Blanco G, Alaniz L et al (2004) CD44 and hyaluronic acid regulate in vivo iNOS expression and metalloproteinase activity in murine air-pouch inflammation. Inflamm Res 53:556–566CrossRefPubMedGoogle Scholar
  9. 9.
    Dentener MA, Vernooy JH, Hendriks S et al (2005) Enhanced levels of hyaluronan in lung of patients with COPD: relationship with lung function and local inflammation. Tohrax 60:114–119CrossRefGoogle Scholar
  10. 10.
    Dinehart SM (2000)The treatment of actinic keratoses. J Am Acad Dermatol 42:525–528CrossRefGoogle Scholar
  11. 11.
    Gebauer K, Brown P, Varigos G (2003) Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Austr J Dermatol 44:40–43CrossRefGoogle Scholar
  12. 12.
    Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol 42:S23–S24CrossRefGoogle Scholar
  13. 13.
    Hascall VC, Majors AK, De la Motte CA et al (2004) Intracellular hyaluronan; a new frontier for inflammation? Biochim Biophys Acta 1673:3–12PubMedGoogle Scholar
  14. 14.
    Jarvis B, Figgit DP (2003) Topical 3%diclofenac in a 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 4(3):203–213PubMedCrossRefGoogle Scholar
  15. 15.
    Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMedGoogle Scholar
  16. 16.
    McEwan LE, Smith JG (1997) Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Austr J Dermatol 38:187–189CrossRefGoogle Scholar
  17. 17.
    Moore AR, Willoughby DA (1995) Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 17:153–156PubMedGoogle Scholar
  18. 18.
    Mortier L, Marchetti P, Delaporte E et al (2002) Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16INK4a tumor suppressor. Cancer Lett 176:205–214CrossRefPubMedGoogle Scholar
  19. 19.
    Nawrat P, Surazynki A, Karna E et al (2005) The effect of hyaluronic acid on interleukin-1-induced deregulation of collagen metabolism in cultured human skin fibroblasts. Pharmacol Res 51:473–477PubMedGoogle Scholar
  20. 20.
    Nelson C, Rigel D, Smith S, Swanson N, Wolf J (2004) Phase IV, open-label assessment of the treatmentof actinic keratosis with 3%diclofenac sodium topical gel (SolarazeTM). J Drugs Dermatol 3(4):401–407PubMedGoogle Scholar
  21. 21.
    Novaes AC, Schaiquevich P, Nasswetter G (2005) Multicenter study of hyaluronic acid obtained by biotechnology to evaluate clinical efficacy and safety in knee osteoarthritis. Int J Clin Pharmacol res 25:1–7PubMedGoogle Scholar
  22. 22.
    Pistorius A, martin M, Willershausen B et al (2005) The clinical application of hyaluronic acid in gingivitis therapy. Quintescence Int 36:531–538Google Scholar
  23. 23.
    Rivers JK, McLean DI (1997) An open study to assess the efficacy and safety of topical 3%diclofenac in a 2.5%hyaluronan acid gel for the treatment of actinic keratoses. Arch Dermatol 133:1239–1242CrossRefPubMedGoogle Scholar
  24. 24.
    Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146:94–100CrossRefPubMedGoogle Scholar
  25. 25.
    Silapunt S, Goldberg LH, Alam M (2003) Topical and light-based treatments for actinic keratoses. Sem Cut Med Surg 22(3):162–170CrossRefGoogle Scholar
  26. 26.
    Spencer JM, Kahn SM, Jiang W et al (1995) Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinoma. Arch Dermatol 131:796–800CrossRefPubMedGoogle Scholar
  27. 27.
    Weindl G, Schaller M, Schafer-Korting M et al (2004) Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol 17:207–213CrossRefPubMedGoogle Scholar
  28. 28.
    Wolf JE, Taylor JR, Tschen E, Kang S (2001) Topical 3.0% diclofenac gel in the treatment of actinic keratoses. Int J Dermatol 40:709–713CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • D. Pirard
    • 1
    • 3
    Email author
  • P. Vereecken
    • 1
  • C. Mélot
    • 2
  • M. Heenen
    • 1
  1. 1.Department of DermatologyErasme Hospital, Erasme universitary HospitalBrusselsBelgium
  2. 2.Intensive CareErasme Hospital, Erasme universitary HospitalBrusselsBelgium
  3. 3.Chaussée de Charleroi, 212BrusselsBelgium

Personalised recommendations